Viatris

Aging Populations And Asia Markets Will Unlock Future Value

AnalystConsensusTarget

Not Invested

Consensus Narrative from 7 Analysts

Published

22 Apr 25

Updated

15 Aug 25

AnalystConsensusTarget's Fair Value

US$11.29

5.6% undervalued

15 Aug

US$10.65

-9.4%

0.4%

Author's Valuation

US$11.3

5.6% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on01 May 25
Fair value Decreased 0.89%

AnalystConsensusTarget Fair Value

US$11.3

5.6% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

1.15%

Pharma revenue growth rate

0.57%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.12%

Calculation

US$419.75m

Earnings '28

35.92x

PE Ratio '28

US$15.08b

Market Cap '28

US$15.08b

Market Cap '28

1.09b

No. shares '28

US$13.87

Share Price '28

US$13.87 Share Price '28

Discounted to 2025 @ 7.15% p.a.

US$11.28

Fair Value '25

Aging Populations And Asia Markets Will Unlock Future Value

Shared on01 May 25Fair value Decreased 0.89%

Shared on01 May 25
Fair value Decreased 0.89%